Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Sep 16;7(3):72. doi: 10.3390/biomedicines7030072

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Effect of MEACL on rat liver gross and histology of HFD-induced hyperlipidemic rats as assessed by hematoxylin and eosin (H&E) staining. (A) Gross appearance of liver, (B) microscopic appearance of liver for normal control, hyperlipidemic control (severe macrovesicular steatosis, severe coagulation necrosis of hepatocyte, and severe cholestasis), and HFD-fed rats treated with atorvastatin (macrovesicular steatosis, lobular inflammation with multiple small foci, and mild cholestasis), 250 mg/kg MEACL (macrovesicular steatosis, lobular inflammation with multiple small foci, and mild cholestasis), 500 mg/kg MEACL (macrovesicular steatosis, lobular inflammation with multiple small foci, and mild cholestasis), and 1000 mg/kg MEACL (macrovesicular steatosis, lobular inflammation with few small foci, and no fibrosis or cholestasis). 100X magnification. Red arrow indicates macrovascular steatosis, and blue arrow indicates the coagulation necrosis of hepatocytes.